Skip to main content
Top
Published in: AIDS and Behavior 8/2011

01-11-2011 | Original Paper

Improving Clinic Attendance and Adherence to Antiretroviral Therapy Through a Treatment Supporter Intervention in Uganda: A Randomized Controlled Trial

Authors: Setor Kunutsor, John Walley, Elly Katabira, Simon Muchuro, Hudson Balidawa, Elizabeth Namagala, Eric Ikoona

Published in: AIDS and Behavior | Issue 8/2011

Login to get access

Abstract

We assessed the effectiveness of the treatment supporter initiative as an intervention in improving clinic attendance for antiretroviral (ARV) drug refills and adherence to antiretroviral therapy (ART) in a cohort of HIV-infected adults. This two-arm randomized controlled trial was undertaken at an HIV clinic in a district hospital in Uganda. A total of 174 adult patients on ART were randomized 1:1 to a standard adherence intervention package plus a treatment supporter intervention (TS arm) or to a standard adherence intervention package (non-TS arm) alone. Clinic attendance for refills and adherence measurements using monthly clinic-based pill counts were monitored for both arms for 28 weeks. Baseline characteristics were similar for both arms. There was a non-significant difference in mean adherence between the TS and non-TS groups at end of follow-up [99.1% (95% CI: 98.3–99.9% vs. 96.3% (95% CI: 94.2–98.3%), P > 0.05]. TS participants had more than four times the odds of achieving optimal adherence (≥95%) [Odds ratio (OR) = 4.51, 95% CI: 1.22–16.62, exact P = 0.027]. TS participants were also more likely to be on time for their clinic appointments: 91.6 vs. 90.1% for TS and non-TS, respectively (OR = 1.19, 95% CI: 0.74–1.91, P > 0.05). Use of patient-selected treatment supporters may be an effective intervention to improve ARV treatment outcomes in resource-constrained settings.
Literature
4.
go back to reference Taiwo B. Adherence to antiretroviral therapy: the more you look, the more you see. Curr Opin HIV AIDS. 2009;4(6):488–92.PubMedCrossRef Taiwo B. Adherence to antiretroviral therapy: the more you look, the more you see. Curr Opin HIV AIDS. 2009;4(6):488–92.PubMedCrossRef
5.
go back to reference Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRef Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.PubMedCrossRef
6.
go back to reference Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.PubMedCrossRef Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.PubMedCrossRef
7.
go back to reference Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
8.
go back to reference Turner BJ. Adherence to antiretroviral therapy by HIV-infected patients. J Infect Dis. 2002;185(S2):S143–51.PubMedCrossRef Turner BJ. Adherence to antiretroviral therapy by HIV-infected patients. J Infect Dis. 2002;185(S2):S143–51.PubMedCrossRef
9.
go back to reference Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18(3):S21–5.PubMedCrossRef Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18(3):S21–5.PubMedCrossRef
10.
go back to reference Laurent C, Diakhate′ N, Fatou Ngom Gueye N, et al. The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16(10):1363–70.PubMedCrossRef Laurent C, Diakhate′ N, Fatou Ngom Gueye N, et al. The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16(10):1363–70.PubMedCrossRef
11.
go back to reference Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS. 2003;17:1369–75.PubMedCrossRef Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS. 2003;17:1369–75.PubMedCrossRef
12.
go back to reference Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009;80(4):669–74.PubMed Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009;80(4):669–74.PubMed
13.
go back to reference Escott S, Walley J. Listening to those on the frontline: lessons for community-based tuberculosis programmes from a qualitative study in Swaziland. Soc Sci Med. 2005;61(8):1701–10.PubMedCrossRef Escott S, Walley J. Listening to those on the frontline: lessons for community-based tuberculosis programmes from a qualitative study in Swaziland. Soc Sci Med. 2005;61(8):1701–10.PubMedCrossRef
14.
go back to reference Wright J, Walley J, Philip A, et al. Direct observation of treatment for tuberculosis: a randomized controlled trial of community health workers versus family members. Trop Med Int Health. 2004;9(5):559–65.PubMedCrossRef Wright J, Walley J, Philip A, et al. Direct observation of treatment for tuberculosis: a randomized controlled trial of community health workers versus family members. Trop Med Int Health. 2004;9(5):559–65.PubMedCrossRef
15.
go back to reference Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(Suppl 2):S96–116.PubMedCrossRef Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(Suppl 2):S96–116.PubMedCrossRef
16.
go back to reference Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2009;50:176–81.CrossRef Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2009;50:176–81.CrossRef
17.
go back to reference Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24(9):1273–80.PubMed Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24(9):1273–80.PubMed
19.
go back to reference Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multi-method approach. J Acquir Immune Defic Syndr. 2010;55(2):221–4.PubMedCrossRef Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: a multi-method approach. J Acquir Immune Defic Syndr. 2010;55(2):221–4.PubMedCrossRef
20.
go back to reference Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed
22.
go back to reference Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentre observational cohort. AIDS. 2006;20(8):1163–9.PubMedCrossRef Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentre observational cohort. AIDS. 2006;20(8):1163–9.PubMedCrossRef
23.
go back to reference Ferradini L, Jeanin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effective assessment. Lancet. 2006;367(9519):1335–42.PubMedCrossRef Ferradini L, Jeanin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effective assessment. Lancet. 2006;367(9519):1335–42.PubMedCrossRef
24.
go back to reference Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S127–33.PubMed Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S127–33.PubMed
25.
go back to reference Oyugi J, Byakika-Tusiime JB, Charlebois ED, et al. Multple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100–2.PubMedCrossRef Oyugi J, Byakika-Tusiime JB, Charlebois ED, et al. Multple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100–2.PubMedCrossRef
26.
go back to reference Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):282–8. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):282–8.
27.
go back to reference Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053–6.PubMedCrossRef Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053–6.PubMedCrossRef
28.
go back to reference Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS. 2006;10:437–42.CrossRef Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS. 2006;10:437–42.CrossRef
29.
go back to reference Degefa A, Sanders EJ, Mekonnen Y, et al. Knowledge and attitudes towards antiretroviral therapy among factory workers participating in a cohort on HIV and AIDS, Addis Ababa, Ethiopia. Ethiop Med J. 2003;41(Suppl 1):75–87.PubMed Degefa A, Sanders EJ, Mekonnen Y, et al. Knowledge and attitudes towards antiretroviral therapy among factory workers participating in a cohort on HIV and AIDS, Addis Ababa, Ethiopia. Ethiop Med J. 2003;41(Suppl 1):75–87.PubMed
30.
go back to reference Norman A, Chopra M, Kadiyala S. Factors related to HIV disclosure in 2 South African communities. Am J Public Health. 2007;97:1775–81.PubMedCrossRef Norman A, Chopra M, Kadiyala S. Factors related to HIV disclosure in 2 South African communities. Am J Public Health. 2007;97:1775–81.PubMedCrossRef
31.
go back to reference Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010;5(5):e10584.PubMedCrossRef Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010;5(5):e10584.PubMedCrossRef
32.
go back to reference Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492–8.PubMedCrossRef Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492–8.PubMedCrossRef
33.
go back to reference Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.PubMedCrossRef Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.PubMedCrossRef
34.
go back to reference Uzochukwu BSC, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24:189–96.PubMedCrossRef Uzochukwu BSC, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24:189–96.PubMedCrossRef
35.
go back to reference Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(3):S123–7.PubMed Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(3):S123–7.PubMed
36.
go back to reference Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 49–62. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 49–62.
37.
go back to reference Horne R. Adherence to medication, a review of existing research. In: Myers L, Midence K, editors. Adherence to treatment in medical conditions. London: Harwood Academic; 1998. p. 285–310. Horne R. Adherence to medication, a review of existing research. In: Myers L, Midence K, editors. Adherence to treatment in medical conditions. London: Harwood Academic; 1998. p. 285–310.
38.
go back to reference Zachariah R, Harries AD, Ishikawa N, et al. Operational research in low-income countries: what, why, and how? Lancet Infect Dis. 2009;9:711–7.PubMedCrossRef Zachariah R, Harries AD, Ishikawa N, et al. Operational research in low-income countries: what, why, and how? Lancet Infect Dis. 2009;9:711–7.PubMedCrossRef
39.
go back to reference Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–21.PubMedCrossRef Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–21.PubMedCrossRef
Metadata
Title
Improving Clinic Attendance and Adherence to Antiretroviral Therapy Through a Treatment Supporter Intervention in Uganda: A Randomized Controlled Trial
Authors
Setor Kunutsor
John Walley
Elly Katabira
Simon Muchuro
Hudson Balidawa
Elizabeth Namagala
Eric Ikoona
Publication date
01-11-2011
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2011
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9927-9

Other articles of this Issue 8/2011

AIDS and Behavior 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.